DEVELOPMENT OF SOLID ORAL DOSAGE FORM CONTAINING OSELTAMIVIR FOR USE IN THE TREATMENT OF INFLUENZA ILLNESS FOR ALL PATIENT GROUPS

Oseltamivir is administered orally for the treatment and prevention of acute, uncomplicated seasonal influenza infections. The white used is a neuraminidase inhibitor available by prescription. Although there are 3 different types (A, B, C) Oseltamivir shows activity against A and B influenza viruses. The main purpose of this study is to develop a generic product that can be used by patient populations of all ages in the treatment and prevention of seasonal flu infections, which have been very common in recent years. After various trial productions, the designed unit formula was implemented by ensuring homogeneity with the dry mix geometric dilution production method due to its low dose of preservative (Sodium Benzoate). The suitability of the study was evaluated by taking into account the physical and chemical analysis features in the European Pharmacopoeia standards.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2024-09-01
DOI
https://doi.org/10.5281/zenodo.13624633
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DEVELOPMENT OF SOLID ORAL DOSAGE FORM CONTAINING OSELTAMIVIR FOR USE IN THE TREATMENT OF INFLUENZA ILLNESS FOR ALL PATIENT GROUPS

Zenodo (CERN European Organization for Nuclear Research)
Influenza Virus Research Studies
article

DEVELOPMENT OF SOLID ORAL DOSAGE FORM CONTAINING OSELTAMIVIR FOR USE IN THE TREATMENT OF INFLUENZA ILLNESS FOR ALL PATIENT GROUPS

article en

Abstract

Oseltamivir is administered orally for the treatment and prevention of acute, uncomplicated seasonal influenza infections. The white used is a neuraminidase inhibitor available by prescription. Although there are 3 different types (A, B, C) Oseltamivir shows activity against A and B influenza viruses. The main purpose of this study is to develop a generic product that can be used by patient populations of all ages in the treatment and prevention of seasonal flu infections, which have been very common in recent years. After various trial productions, the designed unit formula was implemented by ensuring homogeneity with the dry mix geometric dilution production method due to its low dose of preservative (Sodium Benzoate). The suitability of the study was evaluated by taking into account the physical and chemical analysis features in the European Pharmacopoeia standards.

Zenodo (CERN European Organization for Nuclear Research)
Istanbul Commerce University (TR)
Good health and well-being
Openalex Percentile: Top 56%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

DEVELOPMENT OF SOLID ORAL DOSAGE FORM CONTAINING OSELTAMIVIR FOR USE IN THE TREATMENT OF INFLUENZA ILLNESS FOR ALL PATIENT GROUPS · Zenodo (CERN European Organization for Nuclear Research) (2024) | TGRS Research Map | TGRS